Cytori Therapeutics Inc

Find Ratings Reports
CYTX : NASDAQ : Health Care
$0.4799 | %
Today's Range: 0.0 - 0.0
Avg. Daily Volume: 568400.0
07/24/17 - 4:00 PM ET

Financial Analysis

CYTORI THERAPEUTICS INC's gross profit margin for the first quarter of its fiscal year 2017 has significantly decreased when compared to the same period a year ago. Sales and net income fell significantly, underperforming compared to the average company in its industry. CYTORI THERAPEUTICS INC has weak liquidity. Currently, the Quick Ratio is 0.58 which shows a lack of ability to cover short-term cash needs. The company's liquidity has decreased from the same period last year.

During the same period, stockholders' equity ("net worth") has remained virtually unchanged only decreasing by 4.90% from the same quarter last year. Overall, the key liquidity measurements indicate that the company is in a position in which financial difficulties could develop in the future.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12-months. To learn more visit

Income Statement Q1 FY17 Q1 FY16
Net Sales ($mil)1.612.92
EBITDA ($mil)-5.0-4.81
EBIT ($mil)-5.44-5.1
Net Income ($mil)-7.54-5.34

Balance Sheet Q1 FY17 Q1 FY16
Cash & Equiv. ($mil)6.619.36
Total Assets ($mil)29.7732.92
Total Debt ($mil)16.0916.92
Equity ($mil)7.367.74

Profitability Q1 FY17 Q1 FY16
Gross Profit Margin27.0439.14
EBITDA Margin-310.81-164.7
Operating Margin-338.28-174.67
Sales Turnover0.340.37
Return on Assets-81.45-6.45
Return on Equity-329.36-27.44
Debt Q1 FY17 Q1 FY16
Current Ratio0.941.71
Interest Expense0.590.66
Interest Coverage-9.21-7.76

Share Data Q1 FY17 Q1 FY16
Shares outstanding (mil)23.7713.31
Div / share0.00.0
Book value / share0.310.58
Institutional Own % n/a n/a
Avg Daily Volume568918.0663284.0


SELL. This stock’s P/E ratio is negative, making its value useless in the assessment of premium or discount valuation, only displaying that the company has negative earnings per share. Conducting a second comparison, its price-to-book ratio of 3.62 indicates a premium versus the S&P 500 average of 3.07 and a significant discount versus the industry average of 11.44. The price-to-sales ratio is well above the S&P 500 average, but well below the industry average. After reviewing these and other key valuation criteria, CYTORI THERAPEUTICS INC proves to trade at a discount to investment alternatives within the industry.

1 2 3 4 5
premium   discount
  Price/Cash Flow
1 2 3 4 5
premium   discount
CYTX NM Peers 44.01   CYTX NM Peers 43.69

Neutral. The absence of a valid P/E ratio happens when a stock can not be valued on the basis of a negative stream of earnings.

CYTX's P/E is negative making this valuation measure meaningless.


Neutral. The P/CF ratio, a stock’s price divided by the company's cash flow from operations, is useful for comparing companies with different capital requirements or financing structures.

CYTX's P/CF is negative making the measure meaningless.

1 2 3 4 5
premium   discount
  Price to
1 2 3 4 5
premium   discount
CYTX NA Peers 27.93   CYTX NA Peers 0.55

Neutral. A lower price-to-projected earnings ratio than its peers can signify a less expensive stock or lower future growth potential.

Ratio not available.


Neutral. The PEG ratio is the stock’s P/E divided by the consensus estimate of long-term earnings growth. Faster growth can justify higher price multiples.

Ratio not available.

1 2 3 4 5
premium   discount
  Earnings Growth
1 2 3 4 5
lower   higher
CYTX 3.62 Peers 11.44   CYTX -740.00 Peers -7.96

Discount. A lower price-to-book ratio makes a stock more attractive to investors seeking stocks with lower market values per dollar of equity on the balance sheet.

CYTX is trading at a significant discount to its peers.


Lower. Elevated earnings growth rates can lead to capital appreciation and justify higher price-to-earnings ratios.

However, CYTX is expected to significantly trail its peers on the basis of its earnings growth rate.

1 2 3 4 5
premium   discount
  Sales Growth
1 2 3 4 5
premium   discount
CYTX 2.64 Peers 190.63   CYTX -17.67 Peers 434.91

Discount. In the absence of P/E and P/B multiples, the price-to-sales ratio can display the value investors are placing on each dollar of sales.

CYTX is trading at a significant discount to its industry on this measurement.


Lower. A sales growth rate that trails the industry implies that a company is losing market share.

CYTX significantly trails its peers on the basis of sales growth



Latest Stock Upgrades/Downgrades